SNS-032 blocks the CDK7/9 mediated-phosphorylation of Ser2 and Ser5 at the C-terminal domain of RNA polymerase II (RNA pol II), thereby inhibiting transcriptional initiation and elongation.16,17 According to the report, blocking RNA polymerase II is effectively inhibited the proliferation of DLBCL cells.18 So we consided that targeting CDK7/9 should be a significant strategy to treatment DLBCL. Here, CDK7 is linked to diffuse large B-cell lymphoma.